5-Methoxy-N-methyl-N-isopropyltryptamine (also known as 5-MeO-MiPT and moxy) is a lesser-known psychedelic substance of the tryptamine class. 5-MeO-MiPT is chemically related to tryptamines like 5-MeO-DMT and 5-MeO-DiPT. It produces its psychoactive effects through activity at serotonin receptors in the brain.
The synthesis and pharmacology of 5-MeO-MiPT was first reported in 1985 by David Repke and Alexander Shulgin. Its effects in humans was documented in Shulgin’s book TiHKAL (“Tryptamines I Have Known and Loved”).
psychedelic visual distortions. Many users report strong physical and tactile effects that serve to enhance libido and
sexual pleasure. An unpleasant “body load” is also often reported at common to high doses, marked by muscle tension and nausea.
Very little is known about the pharmacological properties, metabolism and toxicity of 5-MeO-MiPT, and it has a
limited history of human use. It has been sold online as a research chemical. It is highly advised to use harm reduction practices when using this substance.
Although preclinical studies suggest that methylone (2-methylamino-1-[3,4-methylenedioxyphenyl]propan-1-one)
and 5-MeO-MIPT (5-methoxy-N-methyl,N-isopropyl tryptamine) may have psychostimulant properties, the
scientific reports about the clinical effects of these agents are scant. We describe a 27-year-old male patient with
substance intoxication after a single ingestion of the mixture of methylone and 5-MeO-MIPT. Though he bought the
drug as pure methylone powder via an internet order, our chemical analyses indicated that the drug was composed of
about 60% methylone (120 mg) and 38% 5-MeO-MIPT (76 mg). This case report suggests that clinicians should be
alert to the possibility of the emergence of methylone or 5-MeO-MIPT intoxication, and substance-related mental
disorder may be complicated by combined use of other psychoactive drugs.
5-MeO-MiPT is a psychedelic and hallucinogenic drug, used by some as an entheogen. It has structural and